

Table SII. Detailed systemic comorbidities, laboratory results, pharmacotherapy and cutaneous comorbidities among non-pruritic and pruritic subjects

Variables	No chronic itch (n = 99)	Chronic itch (n = 54)	p-value	Total
Comorbidities detailed, any presence:				
Arterial hypertension	74	39	0.73	113 (73.9)
Cardiological diseases (total), incl.:	51	27	0.86	78 (51.0)
Ischemic heart disease	32	17	0.92	49 (32.0)
Arrhythmia	20	10	0.80	30 (19.6)
Chronic heart failure	17	10	0.83	27 (17.7)
Asthma and chronic obstructive pulmonary disease	19	7	0.45	26 (17.0)
Neurological diseases (total), incl.:	50	29	0.71	79 (51.6)
Ischaemic	44	29	0.27	73 (47.7)
Amnesia	15	8	0.86	23 (15.0)
Extrapyramidal	5	2	1.00	7 (4.6)
Dementia class	13	8	0.97	21 (13.7)
Joint diseases (total), incl.:	53	37	0.07	90 (58.8)
Osteoarthritis	51	35	0.11	86 (56.2)
Rheumatoid arthritis	2	3	0.35	5 (3.3)
Immobility	3	6	0.07	9 (5.9)
Hypothyroidism	19	13	0.48	32 (20.9)
Hyperthyroidism	4	1	0.66	5 (3.3)
Gastrointestinal diseases (total), incl.:	30	21	0.28	51 (33.3)
Peptic ulcer disease	19	16	0.14	35 (22.9)
Intestinal diseases	18	12	0.55	30 (19.6)
Liver diseases (total), incl.:	13	6	0.92	19 (12.4)
Viral hepatitis	2	1	1.00	3 (2.0)
Fatty liver disease	13	5	0.65	18 (11.8)
Cirrhosis	0	0	n/a	0 (0.0)
Chronic kidney disease	26	19	0.25	45 (29.4)
Benign prostatic hyperplasia	13	6	0.92	19 (12.4)
Diabetes mellitus	23	15	0.53	38 (24.8)
Obesity	28	17	0.68	45 (29.4)
Anaemia	31	18	0.80	49 (32.0)
Psychiatric disorders (total), incl.:	15	9	0.99	24 (15.7)
Anxiety disorders	3	3	0.67	6 (3.9)
Depressive disorders	9	6	0.91	15 (9.8)
Others	5	3	1.00	8 (5.2)
Allergy	16	2	0.04	18 (11.8)
Malignancies (total, excl. cutaneous), incl.:	16	0	0.004	16 (10.5)
Malignant neoplasia, excl. cutaneous	14	0	0.002	14 (9.2)
Lympho- and myeloproliferative disorders	3	0	0.55	3 (2.0)
Chronic venous insufficiency	25	12	0.68	37 (24.2)
Laboratory scores:				
Haemoglobin, mean ± SD	13.0 ± 1.7	12.5 ± 1.3	0.08	12.8 ± 1.5
Creatinine, mean ± SD	0.9 ± 0.3	0.9 ± 0.3	0.55	0.9 ± 0.3
Glomerular filtration rate, mean ± SD	72.9 ± 20.4	69.4 ± 22.5	0.32	71.7 ± 21.2
Aspartate aminotransferase, mean ± SD	22.4 ± 7.0	24.1 ± 8.4	0.19	23.0 ± 7.5
Alanine aminotransferase, mean ± SD	21.9 ± 9.9	20.3 ± 8.7	0.31	21.3 ± 9.5
C-reactive protein, mean ± SD	10.1 ± 35.7	11.2 ± 44.1	0.88	10.4 ± 38.7
Pharmacotherapy [yes vs. no], any presence:	99	54	n/a	153 (100)
Angiotensin converting enzyme inhibitors (ACEI) & angiotensin receptor blockers (ARB) (total), incl.:	61	30	0.47	91 (59.5)
ACEI	42	20	0.52	62 (40.5)
ARB	21	11	0.90	32 (20.9)
α-blockers	10	6	0.94	16 (10.5)
β-blockers	50	35	0.09	85 (55.6)
Ca-blockers	47	22	0.42	69 (45.1)
Diuretics (total), incl.:	43	24	0.90	67 (43.8)
Loop diuretics	16	12	0.35	28 (18.3)
Thiazides	27	13	0.67	40 (26.1)
Sparing diuretics	6	2	0.71	8 (5.2)
Antiarrhythmic drugs (digoxin, propafenone, amiodarone)	5	1	0.42	6 (3.9)
Metformin	13	10	0.37	23 (15.0)
Sulfonylurea derivatives	9	3	0.54	12 (7.8)
Insulin	6	2	0.71	8 (5.2)
Allopurinol	11	7	0.94	18 (11.8)
Statins	49	26	0.87	75 (49.0)
Nitrates	5	6	0.20	11 (7.2)
Antiplatelet drugs (total), incl.:	40	23	0.79	63 (41.2)
Aspirin (ASA)	39	20	0.77	59 (38.6)
P2Y blockers	2	3	0.35	5 (3.3)
Anticoagulants (total), incl.:	18	12	0.55	30 (19.6)
Vitamin K antagonists (VKA)	5	2	1.00	7 (4.6)
Novel oral anticoagulants	6	9	0.07	15 (9.8)
Low molecular weight heparins	8	1	0.16	9 (5.9)

Table SII. Contd.

Variables	No chronic itch (n = 99)	Chronic itch (n = 54)	p-value	Total
Analgesic drugs (total, without aspirin), incl.:	29	16	0.97	45 (29.4)
Non-ASA NSAIDs (with paracetamol), incl.:	27	16	0.76	43 (28.1)
Paracetamol	20	11	0.98	31 (20.3)
Non-ASA NSAIDs	8	6	0.57	14 (9.2)
Opioids	10	7	0.79	17 (11.1)
Antiacids (total), incl.:	23	12	0.89	35 (22.9)
H ₂ -blockers	1	0	n/a	1 (0.7)
Proton-pump inhibitors (PPI)	22	12	1.00	34 (22.2)
Levothyroxine	13	7	0.82	20 (13.1)
Spasmolytics	9	2	0.33	11 (7.2)
Phlebotropic drugs	4	5	0.28	9 (5.9)
Antibiotics	4	3	0.70	7 (4.6)
Psychiatric drugs (w/o selective serotonin reuptake inhibitors (SSRI)), incl.:	18	10	0.96	28 (18.3)
Tricyclic antidepressants	1	1	n/a	2 (1.3)
Tetracyclic antidepressants	5	4	0.72	9 (5.9)
Benzodiazepines	7	4	1.00	11 (7.2)
Antipsychotics (neuroleptics)	8	4	1.00	12 (7.8)
Nootropics	17	11	0.62	28 (18.3)
Drugs with proven beneficial effects on itch (total), incl.:	36	7	0.004	43 (28.1)
Glucocorticoids	7	2	0.49	9 (5.9)
Immunosuppressive drugs	2	1	1.00	3 (2.0)
H ₁ -antihistamines	15	1	0.02	16 (10.5)
SSRI	10	2	0.22	12 (7.8)
Antiepileptics	10	2	0.22	12 (7.8)
Folic acid	10	7	0.79	17 (11.1)
Vitamin B12	12	5	0.79	17 (11.1)
Number of single drugs taken by individual patients, median	6 ± (2.5)	6 ± (2.5)	0.88	6 ± (2.5)
Skin disorders, condition, and symptoms:				
Co-occurring dermatoses, incl.:	99	54	n/a	153 (100)
Lentiginos	78	39	0.36	117 (76.5)
Photoaging	28	14	0.75	42 (27.5)
Actinic keratosis (AK)	12	9	0.59	21 (13.7)
Seborrhoeic keratoses	43	21	0.59	64 (41.8)
Senile angiomas	28	17	0.68	45 (29.4)
Soft fibromas	20	9	0.75	29 (19.0)
Xanthelasma	9	3	0.54	12 (7.8)
Pigmented naevi	31	13	0.34	44 (28.8)
Benign tumours	2	5	0.10	7 (4.6)
Cutaneous malignancies (BCC, SCC, melanoma, lymph.)	3	4	0.24	7 (4.6)
Purpura	10	2	0.22	12 (7.8)
Lower limb oedema	19	8	0.65	27 (17.7)
Varicose veins	41	20	0.60	61 (39.9)
Lower limb ulcers	3	2	1.00	5 (3.3)
Mycoses	18	8	0.76	26 (17.0)
Seborrhoeic dermatitis	2	1	1.00	3 (2.0)
Atopic dermatitis	2	3	0.35	5 (3.3)
Eczema	15	8	0.86	23 (15.0)
Psoriasis	2	2	0.61	4 (2.6)
Rosacea	12	3	0.31	15 (9.8)
Clavi / calluses	7	2	0.49	9 (5.9)
Telogen effluvium	5	2	1.00	7 (4.6)
Teleangiectases	8	3	0.75	11 (7.2)
Miscellaneous	45	26	0.75	71 (46.4)

Significant values are given in bold.